Objective To analyze the correlation between rapid complete remission(CR)after chemotherapy and survival rate in the patients with multiple myeloma(MM).Methods The clinical data of 55 newly diagnosed MM patients received ≥ 4 courses of chemotherapy based on bortezomib and achieved CR for the first time were retrospectively analyzed.Among them,24 patients in group A had rapid CR(achieved CR after 2 courses of chemotherapy),while 31 patients in group B had no rapid CR(achieved CR after＞2 courses of chemotherapy).The progression free survival rate and overall survival rate of the two groups were compared by Kaplan-Meier survival curve.Multivariate Cox regression analysis was used to analyze the independent influencing factors for disease progression.Results The median follow-up time for groups of A and B was 16.2 and 22.9 months,respectively.Among 55 patients,9 patients(16.4％)died and 11 patients(20.0％)experienced disease progression.Kaplan-Meier survival curve analysis showed that the progression free survival rate of the patients in group A was lower than that of the patients in group B(P＜0.05),which of the patients with genetic high-risk factors was lower than that of the patients without genetic high-risk factors(P＜0.05).The results of multivariate Cox regression analysis showed that having genetic high-risk factors and obtaining rapid CR were the independent risk factors for disease progression in MM patients(P＜0.05).Conclusion The MM patients with genetic high-risk factors and rapid CR have a shorter progression free survival period after the chemotherapy based on bortezomib.
维普
万方数据
